Teva Kicks Off ‘The Other TD’ to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Teva Pharmaceutical Industries Ltd: Teva Kicks Off 'The Other TD' to Raise Awareness of Tardive Dyskinesia (TD), with Support from Pro Football Hall of Famer Terrell Davis

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...
Investing.com India

Neurocrine Biosciences shares rise as Q3 earnings, revenue beat expectations

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares rose 3.3% after the neuroscience-focused biopharmaceutical company reported third-quarter financial results that significantly exceeded ...
Investor's Business Daily on MSN

Neurocrine Shares Rise, But Pull Back From Steep Gains, On Strong Ingrezza Quarter

Neurocrine BiosciencesNBIX shares rose late Tuesday after its bread-and-butter drug, Ingrezza, beat third-quarter ...

Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Good day, everyone, and welcome to today's Neurocrine Biosciences Third Quarter 2025 Results Call.
BioSpace

Neurocrine Goes to China To Grow Pipeline in up to $881M TransThera Deal

In Q3, $687 million of its Neurocrine’s income came from sales of Ingrezza, its treatment for the movement disorder tardive dyskinesia, as well as chorea associated with Huntington’s disease. Rounding ...

Neurocrine Biosciences Reports Third Quarter 2025 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2025.